ClinicalTrials.gg
CompletedNCT01138735Updated Feb 18, 2021Results posted

Epiduo Pediatric Acne Study

A Phase 4 interventional study of adapalene/benzoyl peroxide and Topical Gel Vehicle in Acne, sponsored by Galderma R&D. Completed at 25 sites in 2 countries. Open to participants aged 9 Years to 11 Years. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
9 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing adapalene in Acne Vulgaris — none open to participants now, 2 under way, none of them phase 3. Adapalene · Acne Vulgaris.

Enrollment
13th of 30
285 · median 215
Started
2010
with 2 others
Phase 4
11 of 30
none open now
Registered
11th of 30
by date
Lead sponsor
10 of 30
Galderma R&D

Among the 30 studies testing adapalene in Acne Vulgaris, this one is the 13th largest by enrollment, is one of 3 that started in 2010, is one of 11 in phase 4, and was the 11th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 30 studies testing adapalene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About adapalene

Adapalene: first FDA approval 1996 (DIFFERIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies testing adapalene in Acne Vulgaris as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% administered once daily for up to 12 weeks in subjects 9 to 11 years of age with acne vulgaris.

03

Conditions studied

  • Acne

Browse trials for

04

Who can participate

Ages eligible
9 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of acne vulgaris with facial involvement
  • Score of 3 (moderate) on the Investigator's Global Assessment (IGA) scale
  • A minimum of 20 but not more than 100 total lesions (Noninflammatory and/or Inflammatory) on the face (including the nose) at Baseline

Exclusion criteria

Exclusion Criteria:

  • Acne nodule or acne cyst
  • Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), or severe acne requiring systemic treatment
  • Underlying diseases and/or dermatologic conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments
  • Use of prohibited medications prior to the study and/or are unwilling to refrain from such use during the study
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
285 participants (actual)

Study arms

  • Active comparator
    adapalene/benzoyl peroxide

    Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks

    Drug: adapalene/benzoyl peroxide

  • Placebo comparator
    Topical Gel Vehicle

    Topical Gel Vehicle applied topically once daily for 12 weeks

    Drug: Topical Gel Vehicle

Interventions

  • Drugadapalene/benzoyl peroxide

    Drug pages: Adapalene · Benzoyl Peroxide

    daily topical application for 12 weeks

    Also known as: Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5%

  • DrugTopical Gel Vehicle

    daily topical application for 12 weeks

06

What researchers measure

Primary outcomes

  1. Success Rate

    Percentage of subjects rated Clear or Almost Clear with at least 2 grades reduction from Baseline on the Investigator's Global Assessment (IGA)

    Time frame: Baseline to Week 12 (Last Observation Carried Forward [LOCF])

  2. Change From Baseline in Total Lesion Counts

    Time frame: Baseline to Week 12 (LOCF)

Secondary outcomes

  1. Percent Change in Total Lesion Counts From Baseline

    Time frame: Baseline to Week 12 (LOCF)

  2. Change in Inflammatory Lesion Counts From Baseline

    Time frame: Baseline to Week 12 (LOCF)

07

Results

Posted Mar 26, 2013
Limitations and caveats
LOCF data were used for primary efficacy and secondary efficacy data.

Participant flow

Participant flow — Overall Study
MilestoneAdapalene/Benzoyl PeroxideTopical Gel Vehicle
Started142143
Completed134126
Not completed817

Outcome measures

PrimarySuccess Rate

Percentage of subjects rated Clear or Almost Clear with at least 2 grades reduction from Baseline on the Investigator's Global Assessment (IGA)

Time frame:
Baseline to Week 12 (Last Observation Carried Forward [LOCF])
Reported as:
Number · percentage of participant
Success Rate
percentage of participantAdapalene/Benzoyl PeroxideTopical Gel Vehicle
Success Rate47.215.4
Statistical analysis
  • Adapalene/Benzoyl Peroxide vs Topical Gel Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (No adjustment for multiplicity is required. The tests will be conducted as two-sided, each at the 0.05 significance level. The trial will be claimed 'positive' if all primary analyses are shown statistically significant at the 0.05 level.)Cochran-Mantel-Haenszel(CMH) test stratified by analysis center, using general association statistics
PrimaryChange From Baseline in Total Lesion Counts
Time frame:
Baseline to Week 12 (LOCF)
Reported as:
Mean · lesion count change
Change From Baseline in Total Lesion Counts
lesion count changeAdapalene/Benzoyl PeroxideTopical Gel Vehicle
Change From Baseline in Total Lesion Counts-27.6 ± 22.43-3.6 ± 24.44
Statistical analysis
  • Adapalene/Benzoyl Peroxide vs Topical Gel Vehicle · ANCOVA · p = <0.001 (No adjustment for multiplicity is required. The tests will be conducted as two-sided, each at the 0.05 significance level. The trial will be claimed 'positive' if all primary analyses are shown statistically significant at the 0.05 level.)normality assumption is not met. ANCOVA Model: Ranked Change in Total Lesion Counts = Ranked Baseline Lesion Counts, Analysis Center, Treatment.
SecondaryPercent Change in Total Lesion Counts From Baseline
Time frame:
Baseline to Week 12 (LOCF)
Reported as:
Mean · percentage of change in lesion count
Percent Change in Total Lesion Counts From Baseline
percentage of change in lesion countAdapalene/Benzoyl PeroxideTopical Gel Vehicle
Percent Change in Total Lesion Counts From Baseline-55.5 ± 38.99-9.3 ± 48.00
Statistical analysis
  • Adapalene/Benzoyl Peroxide vs Topical Gel Vehicle · Cochran-Mantel-Haenszel · p = <0.001CMH test with row mean difference statistic using relative to an identified distribution(RIDIT) score, controlling for analysis center
SecondaryChange in Inflammatory Lesion Counts From Baseline
Time frame:
Baseline to Week 12 (LOCF)
Reported as:
Mean · lesion count change
Change in Inflammatory Lesion Counts From Baseline
lesion count changeAdapalene/Benzoyl PeroxideTopical Gel Vehicle
Change in Inflammatory Lesion Counts From Baseline-7.4 ± 12.46-0.7 ± 12.46
Statistical analysis
  • Adapalene/Benzoyl Peroxide vs Topical Gel Vehicle · ANCOVA · p = <0.001Ranked Change in Inflammatory Lesion Counts = Ranked Baseline Inflammatory Lesion Counts, Analysis Center, Treatment

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adapalene/Benzoyl Peroxide—0/142 (0%)37/142 (26.1%)
Topical Gel Vehicle—1/143 (0.7%)18/143 (12.6%)
Most frequent serious events
Most frequent serious events
EventAdapalene/Benzoyl PeroxideTopical Gel Vehicle
RIGHT FRONTAL ARTERIOVENOUS MALFORMATIONCongenital, familial and genetic disorders0/1421/143
Most frequent other events
Most frequent other events
EventAdapalene/Benzoyl PeroxideTopical Gel Vehicle
Skin burning sensationSkin and subcutaneous tissue disorders14/1420/143
NasopharyngitisInfections and infestations8/14213/143
Upper respiratory tract infectionInfections and infestations10/1425/143
Skin irritationSkin and subcutaneous tissue disorders8/1420/143

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Adapalene/Benzoyl PeroxideTopical Gel VehicleTotal
<=18 years142143285
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)Adapalene/Benzoyl PeroxideTopical Gel VehicleTotal
Mean10.3 ± 0.7610.4 ± 0.6810.4 ± 0.72
Sex: Female, Male
Sex: Female, Male(Participants)Adapalene/Benzoyl PeroxideTopical Gel VehicleTotal
Female109108217
Male333568
Region of Enrollment
Region of Enrollment(participants)Adapalene/Benzoyl PeroxideTopical Gel VehicleTotal
United States130129259
Canada121426
08

Study locations

25 sites
  • UAB Dermatology Clinical Research
    Birmingham, Alabama 35233, United States
  • Children's Hospital and Health Center Division of Pediatric and Adolescent Dermatology
    San Diego, California 92123, United States
  • Redwood Family Dermatology
    Santa Rosa, California 95403, United States
  • FXM Research Miramar
    Miramar, Florida 33027, United States
  • Adult & Pediatric Dermatology
    Overland Park, Kansas 66211, United States
  • Dermatology Specialists Research
    Louisville, Kentucky 40202, United States
  • Henry Ford Health Systems Department of Dermatology
    Detroit, Michigan 48202, United States
  • Dermcenter PC - Somerset Skin Centre
    Troy, Michigan 48084, United States
  • Minnesota Clinical Study Center A Division of Associated Skin Care Specialists, PA
    Fridley, Minnesota 55432, United States
  • Central Dermatology PC
    Saint Louis, Missouri 63117, United States
  • Skin Specialists, PC
    Omaha, Nebraska 68144, United States
  • Zoe Draelos, MD
    High Point, North Carolina 27262, United States
  • Department of Dermatology - Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • Cininnati Children's Hospital
    Cincinnati, Ohio 45229, United States
  • Haber Dermatology Clinical Research Center
    South Euclid, Ohio 44118, United States
  • Penn State Milton S. Hershey Medical Center - Penn State College of Medicine
    Hershey, Pennsylvania 17033, United States
  • Palmetto Clinical Trial Services, LLC
    Greenville, South Carolina 29607, United States
  • Dermatology Associates of Kingsport, PC
    Kingsport, Tennessee 37660, United States
  • The University of Texas Health Sciences Center at Houston
    Houston, Texas 77030, United States
  • Premier Clinical Research
    Spokane, Washington 99204, United States
  • Guildford Dermatology Specialists
    Surrey, British Columbia V3R 6A7, Canada
  • Nexus Clinical Research
    St John's, Newfoundland and Labrador A1A 5E8, Canada
  • Ultranova Skincare
    Barrie, Ontario L4M 6L2, Canada
  • Lynderm Research, Inc
    Markham, Ontario L3P 1A8, Canada
  • North Bay Dermatology Centre
    North Bay, Ontario P1B 3Z7, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 1 year 7 months after primary completion. A results delay was requested in May 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2010
First posted
Jun 7, 2010
Start
Jun 2010
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results delay requested
May 7, 2012
Results first posted
Mar 26, 2013
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01138735
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jun 7, 2010
Start date
Jun 2010
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Mar 26, 2013
Last update
Feb 18, 2021

Study contacts

Michael Graeber, MD
study director · Galderma R&D
Lorne Albrecht, MD
principal investigator · Guildford Dermatology Specialists
Zoe Draelos, MD
principal investigator · Zoe Draelos, MD
Lawrence Eichenfield, MD
principal investigator · Childrens Hospital and Health Center Division of Pediatric and Adolescent Dermatology
Boni Elewski, MD
principal investigator · UAB Dermatology Clinical Research
Alan Fleischer, MD
principal investigator · Department of Dermatology Wake Forest University Health Sciences
Francisco Flores, MD
principal investigator · FXM Research Miramar
Joseph Fowler, MD
principal investigator · Dermatology Specialists Research
Robert Haber, MD
principal investigator · Haber Dermatology Clinical Research Center
Adelaide Hebert, MD
principal investigator · The University of Texas Health Science Center, Houston
Michael Heffernan, MD
principal investigator · Central Dermatology, PC
David Kaplan, MD
principal investigator · Adult & Pediatric Dermatology
Steven Kempers, MD
principal investigator · Minnesota Clinical Study Center A Division of Associated Skin Care Specialist, PA
Rodion Kunynetz, MD
principal investigator · Ultranova Skincare
Ian Landells, MD
principal investigator · Nexus Clinical Research
Charles Lynde, MD
principal investigator · Lynderm Research Inc.
Russell Mader, MD
principal investigator · Dermatology Associates of Kingsport, PC
Lew Andrew Rosoph, MD
principal investigator · North Bay Dermatology Centre
Joel Schlessenger, MD
principal investigator · Skin Specialists, PC
Michael Spigarelli, MD
principal investigator · Children's Hospital Medical Center, Cincinnati
Linda Stein Gold, MD
principal investigator · Henry Ford Health Systems - Department of Dermatology
Jeffrey Sugarman, MD
principal investigator · Redwood Family Dermatology
William Werschler, MD
principal investigator · Premier Clinical Research
Patricia Westmoreland, MD
principal investigator · Palmetto Clinical Trial Services, LLC
Andrea Zaenglein, MD
principal investigator · Penn State Milton S. Hershey Medical Center - Penn State College of Medicine
George Murakawa, MD
principal investigator · Dermcenter PC; Somerset Skin Centre

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adapalene · Benzoyl Peroxide

Start the discussion